MetaMax is a provider of bio-pharmaceutical drugs designed to treat oncology and metabolic diseases. Their first product, MM-D37K, is a chimeric peptide that shows high therapeutic potential in treating malignant tumors, including glioblastoma, pancreatic cancer, gastrointestinal cancers, melanoma, bladder, and liver cancer. Preclinical studies have demonstrated the effectiveness of this agent in combination with standard chemotherapeutic agents. MetaMax's drugs offer healthcare providers a solution for curing their cancer patients.